A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A 14-WEEK PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY TO DETERMINE THE PHARMACOKINETICS, EFFICACY, SAFETY, AND TOLERABILITY OF TEV-48574 IN ADULT PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE (RELIEVE UCCD

Intervention/treatment:
TEV-48574
Medical condition:
CROHN'S DISEASE
Protocol code:
TV48574-IMM-20036
Control number:
269376
Status:
Closed
Approved:
November 29, 2022
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05499130
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Director, Clinical Research
Organization
Teva Branded Pharmaceutical Products, R&D Inc.
Phone:
888-483-8279
Sponsor
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC

Locations

Manitoba

Teva Investigational Site 11257
Winnipeg, Manitoba, R3A 1R9

Results

See the results from the trial NCT05499130. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?